Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
The halichondrin B analog, eribulin, exerts an anticancer effect, as reported by several clinical and real-life studies on metastatic breast cancer patients. Here, we evaluated efficacy and safety of eribulin, focusing on response to treatment per metastasis type. This monocentric, real-life study was conducted on 31 heavily pretreated patients with metastatic breast cancer. The median progression-free survival and overall survival were 2.0 and 5.5 months, respectively. All patients (12.9%) responding to eribulin were treated in fourth-line setting. Considering response per metastasis type, bone lesions (13.6%) responded more frequently than other metastases to eribulin. Eribulin exhibited a good overall response rate, with the highest response observed for bone metastases.